PTC Therapeutics: Sephience launch drives record revenue and 2 billion USD opportunity
Reading Time: 3 minutes
Business model: PTC Therapeutics focuses on the targeted manipulation of RNA biology to provide treatments for diseases such as Duchenne muscular dystrophy (DMD) and phenylketonuria (PKU). Sephience with blockbuster potential: The launch of Sephience generates record revenue. The peak revenue potential exceeds 2 billion USD. Positive study data: Long-term data for the drug Votoplam against Huntington's disease results in a milestone payment of 50 million USD from Novartis. The biotech stocks form a strong sector trend, with PTC Therapeutics...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
